Nagoya University   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Nagoya Japan (1871)

Organization Overview

First Clinical Trial
2002
NCT00131027
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Department of Cardiology, Nagoya University Graduate School of Medicine | Department of Center for Maternal Neonatal Care, Nagoya University Hospital | Department of Pediatrics, Nagoya University Graduate School of Medicine | Nagoya Medical Center | Nagoya University | Nagoya University Hospital

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 3)

Anemia, Aplastic (Phase 3)

Brain Diseases (Phase 1)

Brain Ischemia (Phase 1)

Cardiomyopathies (Phase 4)

Enuresis (Phase 3)

Febrile Neutropenia (Phase 3)

Fever (Phase 3)

Glomerulonephritis (Phase 1)

Glomerulonephritis, IGA (Phase 1)

Hematologic Diseases (Phase 3)

Hypertension (Phase 4)

Hypertrophy (Phase 4)

Hypertrophy, Left Ventricular (Phase 4)

Hypoxia (Phase 1)

Hypoxia-Ischemia, Brain (Phase 1)

Ischemia (Phase 1)

Leukemia (Phase 3)

Leukemia, Lymphoid (Phase 3)

Muscular Dystrophies (Phase 4)

Muscular Dystrophy, Duchenne (Phase 4)

Neutropenia (Phase 3)

Pancreatic Neoplasms (Phase 2)

Polyradiculoneuropathy (Phase 2)

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 3)

Urinary Incontinence (Phase 3)

Urinary Incontinence, Stress (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 19
  • # of Trial APIs: 36